SRPK1 and breast carcinoma: Given that cisplatin-resistant cells often exhibit cross-resistance to carboplatin and even oxaliplatin3, future studies will be needed to explore whether by manipulating the PTMs of SRPK1, we can universally re-sensitize the resistant breast cancer cells to these compounds.